Skip to main content
. Author manuscript; available in PMC: 2019 Nov 27.
Published in final edited form as: J Biopharm Stat. 2015;25(4):812–829. doi: 10.1080/10543406.2014.920858

Table 1.

Distributions of log10 HIV-1 RNA (copies per mL of cervico-vaginal lavage fluid), phase I Carraguard trial, Chiang Rai, Thailand.

Group N % ND % NQ % Q Median (Q1, Q3)
At the start of each cycle (day zero)
Cycle 1 58 19 16 66 2.37 ( NQ, 3.07)
Cycle 2 53 19 21 60 2.04 ( NQ, 2.96)
Cycle 3 52 27 17 56 2.12 ( ND, 2.87)
On day seven, by treatment
Carraguard® 54 39 19 43 NQ ( ND, 2.38)
Placebo gel 55 44 15 42 NQ ( ND, 2.59)
No product 54 24 20 56 2.03 ( NQ, 2.9)
On day 14, by treatment
Carraguard® 51 22 24 55 2.11 ( NQ, 2.73)
Placebo gel 54 37 13 50 NQ ( ND, 2.95)
No product 53 25 21 55 2.13 ( NQ, 3.07)

ND: none detected; NQ: detected but not quantifiable; Q: quantifiable (lower limit is 1.90 on the log10 scale). Q1: first quartile; Q3: third quartile.